BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34339501)

  • 1. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.
    Dhakal B; Abedin S; Fenske T; Chhabra S; Ledeboer N; Hari P; Hamadani M
    Blood; 2021 Oct; 138(14):1278-1281. PubMed ID: 34339501
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.
    Tamari R; Politikos I; Knorr DA; Vardhana SA; Young JC; Marcello LT; Doddi S; Devlin SM; Ramanathan LV; Pessin MS; Dunn E; Palazzo M; Bravo CD; Papanicolaou GA; Kamboj M; Perales MA; Chung DJ; Shah GL
    Blood Cancer Discov; 2021 Nov; 2(6):577-585. PubMed ID: 34778798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
    Ghione P; Gu JJ; Attwood K; Torka P; Goel S; Sundaram S; Mavis C; Johnson M; Thomas R; McWhite K; Darrall A; DeMarco J; Kostrewa J; Mohr A; Rivas L; Neiders M; Suresh L; Segal BH; Griffiths EA; Ramsperger V; Shen L; Hernandez-Ilizaliturri FJ
    Blood; 2021 Sep; 138(9):811-814. PubMed ID: 34189565
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
    Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
    Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
    [No Abstract]   [Full Text] [Related]  

  • 6. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
    Rimar D; Slobodin G; Paz A; Henig I; Zuckerman T
    Ann Rheum Dis; 2021 Oct; 80(10):1354-1355. PubMed ID: 34049853
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
    Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
    Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Gastinne T; Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Tessoulin B; Jullien M; Vanthygem S; Béné MC; Moreau P; Le Gouill S; Chevallier P
    Br J Haematol; 2022 Jan; 196(2):360-362. PubMed ID: 34476803
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
    Khawaja F; Papanicolaou G; Dadwal S; Pergam SA; Wingard JR; Boghdadly ZE; Abidi MZ; Waghmare A; Shahid Z; Michaels L; Hill JA; Kamboj M; Boeckh M; Auletta JJ; Chemaly RF
    Transplant Cell Ther; 2023 Jan; 29(1):10-18. PubMed ID: 36273782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
    Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
    Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
    Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
    Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy.
    Reimann H; Kremer AN; Blumenberg V; Schmidt K; Aigner M; Jacobs B; Eisenhauer N; Kämpf A; Rösler W; Kharboutli S; Mougiakakos D; Lang V; Lischer C; Irrgang P; Leppkes M; Gonzalez JV; Krönke G; Kremer AE; Tenbusch M; Bruns H; Harrer T; Müller F; Schett G; Mackensen A; Subklewe M; Völkl S
    Blood Adv; 2023 May; 7(10):2066-2069. PubMed ID: 36206194
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
    Dahiya S; Luetkens T; Lutfi F; Avila S; Iraguha T; Margiotta P; Hankey KG; Lesho P; Law JY; Lee ST; Baddley J; Kocoglu M; Yared JA; Hardy NM; Rapoport AP; Atanackovic D
    Blood Adv; 2022 Jan; 6(2):686-689. PubMed ID: 34941995
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.
    Redjoul R; Le Bouter A; Parinet V; Fourati S; Maury S
    Lancet Haematol; 2021 Oct; 8(10):e681-e683. PubMed ID: 34487683
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
    Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
    Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.